Thomas Willard, MD
Urology · West Columbia, SCNPI 1477585305
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.7%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Photocure Inc at 55.8% of the total. Reporting peaked in 2021 at $3,362 and has fallen 77.2% since, to $767 in 2025.
Across 215 payments — averaging $58.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Photocure Inc$7K
- Intuitive Surgical$2K
- Coloplast$1K
- AbbVie$527
- Boston Scientific$485
- Astellas Pharma US Inc$256
- plus $2K from 31 others
Across 19 payments — averaging $3658.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Photocure Inc$63K
- Coloplast$6K
What the payments were for
- Consulting fees$4,50036%
- Speaking & faculty fees$1,40011%
- Travel & lodging$8036%
- Food & beverage$5,57845%
- Education$2002%
- Gifts$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Photocure Inc | 14 | $6,975 |
| Intuitive Surgical | 11 | $1,553 |
| Coloplast | 80 | $1,045 |
| AbbVie(2 entities) | 26 | $527 |
| Boston Scientific | 7 | $485 |
| Astellas Pharma US Inc | 7 | $256 |
| Janssen Scientific Affairs, LLC | 2 | $234 |
| Johnson & Johnson | 11 | $232 |
| Urogen Pharma, Inc. | 7 | $157 |
| LSI Solutions Inc | 1 | $113 |
| Ferring Pharmaceuticals Inc. | 7 | $111 |
| Pfizer | 5 | $78 |
| Myriad Genetic Laboratories, Inc. | 4 | $70 |
| Progenics Pharmaceuticals, Inc. | 3 | $63 |
| Sumitomo Pharma America, Inc. | 2 | $60 |
| Siemens Medical Solutions USA, Inc. | 1 | $57 |
| Olympus America Inc. | 1 | $44 |
| Rochester Medical Corporation | 2 | $43 |
| Amgen | 2 | $37 |
| Antares Pharma, Inc. | 2 | $32 |
| Merck | 1 | $31 |
| Endo Pharmaceuticals Inc. | 2 | $28 |
| Zyla Life Sciences, Inc. | 2 | $23 |
| Laborie Medical Technologies Corp. | 2 | $23 |
| ABC Home Medical Supply, Inc. | 1 | $22 |
| Bayer | 1 | $22 |
| Teleflex LLC | 1 | $19 |
| Blue Earth Diagnostics | 1 | $19 |
| Urovant Sciences Inc | 1 | $17 |
| Innovation Technologies Inc | 1 | $17 |
| Endo USA, Inc. | 1 | $17 |
| Procept Biorobotics Corporation | 1 | $15 |
| Ambu Inc. | 1 | $15 |
| SRS Medical Systems, Inc. | 1 | $14 |
| Hollister Incorporated | 1 | $13 |
| Medtronic | 1 | $12 |
| RGH Enterprises LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cysview$6,544
- Da Vinci Surgical System$1,251
- Erleada$234
- ZYTIGA$234
- RUNNING DEVICE$113
- JNW URTRAC$113
- Balversa$111
How this compares
$12,490 in reported general payments places this provider in the 85th percentile of 196 urology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 52 | $36,780 |
| GemtesaVibegron | 13 | $9,551 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 240 | $7,074 |
| Potassium Citrate ErPotassium Citrate | 16 | $2,153 |
| Solifenacin Succinate | 42 | $1,935 |
| Dutasteride | 30 | $1,716 |
| Tamsulosin Hcl | 94 | $1,675 |
| Oxybutynin Chloride ErOxybutynin Chloride | 17 | $792 |
| Oxybutynin Chloride | 25 | $392 |
| Ketorolac Tromethamine | 27 | $377 |
| Finasteride | 36 | $359 |
| Levofloxacin | 109 | $257 |
| Doxycycline Hyclate | 29 | $196 |
| Bicalutamide | 11 | $142 |
| Ciprofloxacin Hcl | 20 | $115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $256 | $36,78052 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $60 | $9,55113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 196 urology providers in South Carolina.
Other urology in West Columbia
- Phillip WestbrookWest Columbia$14K
- Griffin MorrissonWest Columbia$14K
- Keith BrightbillWest Columbia$12K
- Scott SweazyWest Columbia$8K
- John BeasleyWest Columbia$8K
- David LambWest Columbia$7K
- Neal ShoreMyrtle Beach$3.2M
- Manish PatelElgin$213K
- Sandip PrasadCharleston$177K
- Benjamin DropkinGreenville$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.